Aldeyra Therapeutics, Inc. (the Company) was incorporated in the state of Delaware on August 13, 2004 as Neuron Systems, Inc. On December 20, 2012, the Company changed its name to Aldexa Therapeutics, Inc. and on March 17, 2014, the Company changed its name to Aldeyra Therapeutics, Inc. The Company is developing a treatment for diseases thought to be related to high levels of free aldehydes, naturally occurring pro-inflammatory toxins.
The Company’s principal activities to date include raising capital and research and development activities.
The Company’s initial public offering of common stock (Initial Public Offering) was completed on May 7, 2014.
As of August 6, 2014, there were 5,565,415 shares of the registrant’s common stock issued and outstanding.